Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide

Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmaceutics
Main Authors: Abeer, Muhammad Mustafa, Meka, Anand Kumar, Pujara, Naisarg, Kumeria, Tushar, Strounina, Ekaterina, Nunes, Rute, Costa, Ana, Sarmento, Bruno, Hasnain, Sumaira Z., Ross, Benjamin P., Popat, Amirali
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6723263/
https://ncbi.nlm.nih.gov/pubmed/31430872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics11080418
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados